VACCINES SUMMIT BOSTON 2023

www.biogatesc.com/events/va-cc-in-e/
Boston Marriott Newton Hotel, Newton, MA, USA
+91 9160 331 607
priyanka.m@bsc.events
ADVISORY BOARD MEMBERS

LUIS RÍOS NOGALES GARCES
EXECUTIVE VP & CDO
ILIAD BIOTECNOLOGIES, USA

SABINE HAUCK
EVP CORPORATE DEVELOPMENT
LEUKOCARE AG, GERMANY

DON J. DIAMOND
PROFESSOR
DEPARTMENT OF HEMATOLOGY & HEMATOPOIETIC CELL TRANSPLANTATION
CITY OF HOPE, USA

WILLIAM R. JACOBS JR.
LEO & JULIA FORCHHEIMER CHAIR
MICROBIOLOGY & IMMUNOLOGY
ALBERT EINSTEIN COLLEGE OF MEDICINE, USA

ORGANIZING COMMITTEE MEMBERS

SACHIN SRAVAN
FOUNDER & CEO
BIOGATE SCIENTIFIC CENTER

PRIYANKA M
PROJECT DIRECTOR - CONFERENCES
BIOGATE SCIENTIFIC CENTER
WELCOME MESSAGE

I want to personally welcome all of the delegates and speakers to the hub, as fellow Bostonians refer to this vibrant and pulsating city. This excellent locale for a conference brings together the very best talent in the vaccine field. While the conference site might be in Waltham, everything in the metro area is influenced by the dynamic commercial and academic environment in the hub locale. We have assembled a topnotch group of speakers and advisors to guide the content and direction of this meeting. The choice of topics spans the gamut of cutting edge science, commercial development, and clinical application of vaccines for a whole range of diseases in the global sense. Diseases of the developing world, the tropical climates, Africa and the middle east, and the western world are all covered by individual presentations by noted authorities in each of these disciplines. The meeting will cover both delivery mechanisms as well as individual vaccine examples for major disease groups plaguing our planet. Speakers come from national health agencies from Europe and the USA, large pharma represented by some of the most prestigious names, small biotechs and startups, and faculty from European and American academia. One could not ask for a more diverse group of speakers who will enlighten us on a range of topics than span the vaccine universe. I encourage anyone who is devoted to this discipline and its many allied academic and commercial applications to register to participate as this will be the highlight of the many conferences that will bombard you to attend. This is a "not to be missed" gathering that will enrich all of us, so when we return to our workplaces, we will have learned something new and cutting edge to incorporate into our own work and discoveries.

It is my great pleasure to welcome all participants to the Vaccine Summit Boston 2023. I am excited to meet colleagues from the vaccine world again on-site at this vibrant biotech community in Massachusetts. After a lean period, distinguished presenters from the USA and Europe will eventually regather in Boston to share their knowledge and experience with the vaccine community. An opportunity, that provides scientific insights combined with networking opportunities across all areas. It is this scientific exchange that helps us to develop and excel in our field. With the booster of recent years, the vaccine field emerged into new areas. The Vaccine Summit Boston 2023 will present new applications of the RNA vaccine technology for prophylactic vaccines. We will also hear how vaccines can benefit from cell therapies. I am particularly excited that this conference will also delve into therapeutic vaccination concepts, aiming to treat infectious diseases or cancer. I am looking forward to fruitful interactions among participants and to an inspiring conference.

SABINE HAUCK
EXECUTIVE VICE-PRESIDENT
CORPORATE DEVELOPMENT
LEUKOCARE AG, GERMANY
FOR SPONSORSHIP AND EXHIBITION OPPORTUNITIES, PLEASE CONTACT:

SACHIN SRAVAN
Email: sachin@bsc.events

FOR SPEAKING OPPORTUNITIES AND DELEGATE SERVICES, PLEASE CONTACT:

PRIYANKA M
Email: priyanka.m@bsc.events

TARGET AUDIENCE

- C-LEVEL EXECUTIVES
- SENIOR SCIENTISTS
- DECISION MAKERS
- PRESIDENTS, VPS & SVPS
- DRUG DEVELOPERS
- ACADEMICIANS
- MANUFACTURERS
- RESEARCHERS & DEVELOPERS
- DIRECTORS
- HEALTHCARE PROFESSIONALS
- PRODUCT DEVELOPERS
- REGULATORY SPECIALISTS
- PRINCIPAL INVESTIGATORS
- CONSULTANTS

SESSION TRACKS

- NOVEL LIVE ATTENUATED VACCINES
- CANCER VACCINES
- HIV VACCINE
- COVID-19 VACCINE R&D
- INFLUENZA & RESPIRATORY
- BACTERIAL, TB & MALARIAL VACCINES
- EMERGING & RE-EMERGING DISEASES
- BIOPROCESSING & MANUFACTURING
- CLINICAL TRIALS
- VACCINES SAFETY & EFFICACY
- IMMUNE PROFILING
- NEW VACCINE DEVELOPMENT
- VACCINE ADJUVANTS
- DNA, RNA & SUBUNIT VACCINES
- VACCINE DELIVERY SYSTEMS
- VACCINES QA & QC
- VETERINARY VACCINES
- VACCINE DESIGN
VSBOSTON23 (EVENT SCHEDULE)

CONFERENCE VENUE
BOSTON MARRIOTT NEWTON HOTEL
2345 COMMONWEALTH AVENUE
NEWTON, MA 02466, USA

MAY 22
MONDAY

08:00  Inaugural Ceremony
08:10  Keynote Talks - I
09:00  Pre-Recorded Presentation
09:30  Refreshment break - I
09:40  Session Talks - I
12:40  Lunch
13:30  Session Talks - II
16:30  Refreshment break – II
16:40  Session Talks - II (Cont.)
17:40  Poster Presentation

MAY 24
WEDNESDAY

08:10  Keynote Talks - III
09:00  Session Talks - V
10:00  Refreshment break - I
10:10  Session Talks - V (Cont.)
11:40  Session Talks - VI
13:10  Lunch
**Day 1 Schedule**

**Monday, May 22**

**Inaugural Ceremony**
8:00-8:10

**Keynote Talks - I**

**8:10-9:00**

**DON J. DIAMOND**  
Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, USA  
Title: Development of CMV-MVA-Triplex vaccine for reduction of cytomegalovirus complication post-transplantation

**9:00-9:30**

**LUIGI BUONAGURO (Pre-Recorded Presentation)**  
Director, Innovative Immunological Models Unit, National Cancer Institute - IRCCS “Pascale”  
Title: Viral antigens as cancer vaccines

**Refreshment Break - I (10 Mins)**

**Session Talks - I**

**Cancer Vaccines | Novel Live Attenuated Vaccines | HIV Vaccines**

**9:40-10:10**

**WIM VAN CRIEKINGE**  
Chief Scientific Officer, myNEO, USA  
Title: Exploring and validating clinical validity of lncRNAs as a novel source of immunogenic targets for immunotherapy

**10:10-10:40**

**ELI GILBOA**  
Dodson Professor for Microbiology & Immunology, University of Miami, USA  
Title: Vaccination against a common set of neoantigens induced in tumors and pathogen infected cells

**10:40-11:10**

**ADAM E. SNOOK**  
Associate Professor, Department of Pharmacology, Physiology, & Cancer Biology, Thomas Jefferson University, USA  
Title: Adjuvant vaccines to prevent GI cancer recurrence

**11:10-11:40**

**JUDITH ALAMARES-SAPUAY**  
Senior Scientist, Global Immunology, Vaccines R&D, Sanofi, USA  
Title: Optimization and characterization of a live attenuated respiratory syncytial virus vaccine candidate

**11:40-12:10**

**PIROUZ DAFTARIAN**  
Director of Scientific Engagement, Crown Bioscience, MBLI, and JSR Life Sciences, USA  
Title: Today’s metrics of immunogenicity of cancer vaccines

**This program is subject to change**
<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:10-12:40</td>
<td><strong>MARTIN MOORE</strong></td>
<td><strong>Founder &amp; Chief Scientific Officer, Meissa Vaccines, USA</strong></td>
<td>Safety and immunogenicity of a live, attenuated RSV vaccine in RSV-naive children 6 to 36 months of age</td>
</tr>
<tr>
<td>13:30-14:00</td>
<td><strong>SARITA K. ACHARYA</strong></td>
<td><strong>Principal Scientist, Global Biologics, United States Pharmacopoeia, USA</strong></td>
<td>Ensuring quality and safety of mRNA vaccines today &amp; tomorrow</td>
</tr>
<tr>
<td>14:00-14:30</td>
<td><strong>KUN ZHOU</strong></td>
<td><strong>Project Lead, GeneLeap Biotech, USA</strong></td>
<td>A Novel mRNA-based therapeutic vaccine to target HPV16-associated cervical lesions</td>
</tr>
<tr>
<td>14:30-15:00</td>
<td><strong>VIRA BITKO</strong></td>
<td><strong>Vice President, Head of Vaccine Therapeutics, RVAC Medicines, USA</strong></td>
<td>Development of RSV mRNA vaccine</td>
</tr>
<tr>
<td>15:00-15:30</td>
<td><strong>DON J. DIAMOND</strong></td>
<td><strong>Professor, Department of Hematology &amp; Hematopoietic Cell Transplantation, City of Hope, USA representing GeoVax, USA</strong></td>
<td>Assessment of Geo-CM04S1 for prevention of COVID-19 in immunocompromised cell therapy patients; An open-label safety study</td>
</tr>
<tr>
<td>15:30-16:00</td>
<td><strong>FENG XUAN</strong></td>
<td><strong>Co-founder, President &amp; CTO, Spear Bio, USA</strong></td>
<td>A novel ultrasensitive cell-free SARS-CoV-2 neutralizing antibody assay for measuring humoral immune response of vaccine with high lab-to-lab consistency</td>
</tr>
<tr>
<td>16:00-16:30</td>
<td><strong>URMI CHHEDA</strong></td>
<td><strong>Associate Scientist, GreenLight Biosciences, USA</strong></td>
<td>Stability of mRNA LNP</td>
</tr>
<tr>
<td>16:40-17:10</td>
<td><strong>THORSTEN VOGEL</strong></td>
<td><strong>Director, Technology &amp; External Innovation, Global Immunology, Research, Sanofi, USA</strong></td>
<td>Proof of concept of multivalent/octavalent vaccine platforms in naïve ferrets to deliver Influenza HA and NA antigens together for improved immunogenicity against NA compared to standard Influenza vaccines</td>
</tr>
<tr>
<td>17:10-17:40</td>
<td><strong>MITHILA FERDOUS</strong></td>
<td><strong>Senior Scientist, Department of Global Immunology, Sanofi, USA</strong></td>
<td>Evaluation of novel influenza mRNA vaccine supplemented with neuraminidase to improve protection against disease in ferrets</td>
</tr>
</tbody>
</table>

**THIS PROGRAM IS SUBJECT TO CHANGE**
### MAY 23

**Tuesday**

#### KEYNOTE TALKS - II

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00-8:50</td>
<td><strong>SABINE HAUCK</strong></td>
<td>EVP Corporate Development, Leukocare AG, Germany</td>
</tr>
<tr>
<td></td>
<td>Title: Next generation in formulation development for vaccines</td>
<td></td>
</tr>
<tr>
<td>8:50-9:40</td>
<td><strong>WILLIAM R. JACOBS JR.</strong></td>
<td>Leo &amp; Julia Forchheimer Chair, Microbiology and Immunology, Albert Einstein College of Medicine, USA</td>
</tr>
<tr>
<td></td>
<td>Title: Current progress towards a new tuberculosis vaccine</td>
<td></td>
</tr>
</tbody>
</table>

#### REFRESHMENT BREAK - I (10 MINS)

#### SESSION TALKS - III

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:50-10:20</td>
<td><strong>TBA</strong></td>
<td>TBA</td>
</tr>
<tr>
<td></td>
<td>Title: TBA</td>
<td></td>
</tr>
<tr>
<td>10:20-10:50</td>
<td><strong>AARON ESSER-KAHN</strong></td>
<td>Associate Professor, Pritzker School of Molecular Engineering, University of Chicago, USA</td>
</tr>
<tr>
<td></td>
<td>Title: The challenge of making every vaccine safer and more effective: Engineering signal processing of innate immune cells</td>
<td></td>
</tr>
<tr>
<td>10:50-11:20</td>
<td><strong>MAGDALENA TARY-LEHMANN</strong></td>
<td>Chief Scientific Officer, Cellular Technology Limited, USA</td>
</tr>
<tr>
<td></td>
<td>Title: Immunogenicity assessment in support of gene therapy programs - use of ELISPOT</td>
<td></td>
</tr>
<tr>
<td>11:20-11:50</td>
<td><strong>DE-CHU CHRISTOPHER TANG</strong></td>
<td>Chief Executive Officer, VaxDome, USA</td>
</tr>
<tr>
<td></td>
<td>Title: Broad-spectrum vaccine-antiviral hybrid without constraints imposed by viral mutations</td>
<td></td>
</tr>
<tr>
<td>11:50-12:20</td>
<td><strong>JOSEPH G. JOYCE</strong></td>
<td>Distinguished Scientist, Vaccine Process R&amp;D (VPRD), Merck, USA</td>
</tr>
<tr>
<td></td>
<td>Title: Development and clinical assessment of a novel 21-valent pneumococcal conjugate vaccine (V116)</td>
<td></td>
</tr>
</tbody>
</table>

**Key note**

This program is subject to change.
12:20-12:50  VICTOR BRONSHTEIN
President & CSO, Universal Stabilization Technologies (Vitrilife), USA
Title: VitriLife® technology platform for industrial production and mucosal delivery of thermostable vaccines and other biopharmaceuticals

LUNCH BREAK (50 MINS)

13:40-14:10  MARK EMALFARB
President & CEO, Dyadic International, USA
Title: Transforming manufacturing & closing the technology gap in least developed countries

14:10-14:40  KEVIN P. KILLEEN
Chief Scientific Officer, Matrivax, USA
Title: MVX01: A global, serotype-independent, pneumococcal protein fusion vaccine candidate

SESSION TALKS - IV

CLINICAL TRIALS | VACCINE DELIVERY SYSTEMS | BIOPROCESSING & MANUFACTURING

14:40-15:10  ROBERT DILLMAN
Chief Medical Officer, AIVITA Biomedical, USA
Title: Clinical progress with personal dendritic cell vaccines for cancer and covid infection

15:10-15:40  VANESSA ELHARRAR
Vice President, Vaccines Business Strategy Lead, PPD, USA
Title: Key considerations for vaccine development in special populations (elderly, pregnant, immuno-compromised, pediatrics)

15:40-16:10  MICHAEL SUMNER
Chief Medical Officer, Inovio, USA
Title: Advancing DNA medicines: Clinical updates on Ebola and recurrent respiratory papillomatosis candidates

16:10-16:40  SHAHIN GHARAKHANIAN
MD Consulting LLC, CIC: Cambridge Innovation Center, USA
Title: P28GST, a therapeutic vaccine for the treatment of chronic inflammatory diseases. Data supporting clinical indication and case study

REFRESHMENT BREAK - II (10 MINS)

16:50-17:20  LYNDA TUSSEY
Chief Development Officer, Vaxess Technologies, USA
Title: Phase 1 clinical evaluation of VX-103: A sustained-release, patch-based influenza vaccine delivered on the MIMIX™ platform

THIS PROGRAM IS SUBJECT TO CHANGE
<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Institution</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:20-17:50</td>
<td>JAMES Z. DENG</td>
<td>Associate Principal Scientist, Vaccine Analytical R&amp;D, Merck, USA</td>
<td>Analytical strategies for characterization of multi-valent pneumococcal conjugate vaccine</td>
</tr>
<tr>
<td>17:50-18:20</td>
<td>MIC MCGOLDRICK</td>
<td>Associate Director Global CMC Policy, Merck&amp;Co., Inc. on behalf of IFPMA, USA</td>
<td>Accelerating access to vaccines – Next steps beyond the pandemic</td>
</tr>
<tr>
<td>18:20-18:50</td>
<td>MATTHEW A. COLEMAN</td>
<td>Staff Scientist, Lawrence Livermore National Laboratory, USA</td>
<td>Co-translational cell-free expression of Chlamydial membrane bound proteins for antigen discovery and application</td>
</tr>
</tbody>
</table>
**MAY 24**

**Wednesday**

**KEYNOTE SESSION - III**

**8:10-9:00**

**ADRIAN V. S. HILL**
Director, The Jenner Institute, University of Oxford, UK
Title: Phase 3 progress with a high efficacy malaria vaccine

**SESSION TALKS - V**

**REFRESHMENT BREAK - I (10 MINS)**

**9:00-9:30**

**TRUDY MORRISON**
Professor, University of Massachusetts Chan Medical School, USA
Title: The Respiratory syncytial virus G protein enhances the immune responses to the RSV F protein in an enveloped virus-like particle vaccine candidate

**9:30-10:00**

**CHRISTOPHER P. LOCHER**
Co-Founder & CEO, Versatope Therapeutics, USA
Title: Structure and function of a broad-strain influenza vaccine using nano-vesicles

**10:10-10:40**

**JUN LIN**
Professor of Infectious Disease, The University of Tennessee, USA
Title: Enterobactin-based immune intervention against Gram-negative pathogens

**10:40-11:10**

**SELVAKUMAR SUBBIAN**
Principal Investigator, Public Health Research Institute, New Jersey Medical School, Rutgers University, USA
Title: Immune response of BCG vaccination is shaped by the nature and infectious inoculum of pathogenic Mycobacterium tuberculosis

**11:10-11:40**

**CHINNASWAMY JAGANNATH**
Professor, Pathology & Genomic Medicine, Houston Methodist Research Institute & Weill Cornell Medical College, USA
Title: New generation adenoviral and mRNA-based tuberculosis vaccines

**THIS PROGRAM IS SUBJECT TO CHANGE**
### Session Talks - VI

**Vaccine Adjuvants | Emerging & Re-emerging Diseases**

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:40-12:10</td>
<td><strong>LEI JIN</strong></td>
<td>Mucosal vaccine for the aged: Decode cyclic dinucleotides adjuvanticity</td>
<td>University of Florida, USA</td>
</tr>
<tr>
<td>12:10-12:40</td>
<td><strong>JOSEPH M. VINETZ</strong></td>
<td>Exploiting bacterial genomics to delineate mechanisms of pathogenesis, enabling vaccine development for an emerging/re-emerging zoonotic infectious disease</td>
<td>Yale University School of Medicine, USA</td>
</tr>
<tr>
<td>12:40-13:10</td>
<td><strong>TBA</strong></td>
<td>TBA</td>
<td>TBA</td>
</tr>
</tbody>
</table>

**Lunch Break (60 Mins)**

---

**WE HAVE SESSION AND POSTER SLOTS AVAILABLE**

To present your work at VSBOSTON, contact: priyanka.m@bsc.events

---

**THIS PROGRAM IS SUBJECT TO CHANGE**
POSTER SESSION

POSTER-01  ANDREW J. RENNEKAMP
Medical Science Liaison, CSL Seqirus, USA
Title: Real world study of adjuvanted influenza vaccine in preventing cardio-respiratory related hospitalizations in the elderly during the 2019-2020 U.S. influenza season

POSTER-02  MARK EMALFARB
President & CEO, Dyadic International, USA
Title: Development of the thermophilic filamentous fungus *Thermothelomyces heterothallica* C1 into a prominent human and animal vaccines production platform

POSTER-03  ABEL E. VASQUEZ
TBA
Title: The surface immunogenic recombinant protein from *Streptococcus agalactiae* is a potential new vaccine adjuvant

POSTER-04  KAROLYNE WARNY
Senior Research Associate, Global Immunology, Sanofi, USA
Title: Preclinical benefit of recombinant NA addition to HA-based protein vaccine reduced disease severity in a ferret challenge model

WE HAVE SESSION AND POSTER SLOTS AVAILABLE
To present your work at VSBOoston, contact: priyanka.m@bsc.events

Thank you
SEE YOU AT VSBOston23

THIS PROGRAM IS SUBJECT TO CHANGE